Peptides DB
Research-centric peptide and protocol reference hub

Orforglipron (LY-3502970) record · updated 7h ago

Metabolic & appetiteGrade A · human clinicalResearch use only
All 1 studiesJump to the evidenceCompare
What is Orforglipron (LY-3502970) used for?

Orforglipron (LY-3502970) is an investigational oral small-molecule GLP-1 receptor agonist studied for type 2 diabetes and obesity, offering pill-based dosing without injection.

Primarily researched for · Metabolic & appetite

Development stage

where Orforglipron (LY-3502970) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 24 registered trials. It describes the research record, not a recommendation.

Identity
NameOrforglipron (LY-3502970)
Full name—
Sequence—
ClassWeight Loss
Research levelExtensively Studied
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
Metabolic & appetite: Healing 0.0, Muscle 0.0, Metabolic 5.0, Neuro 0.0, Sleep 0.0, Immune 0.0, Skin 0.0Metabolic & appetite — 5.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin0.00.05.00.00.00.00.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies1
Human / animal / cellular1 / 0 / 0
Highest trial phase—
Years covered2006–2024
Latest study14d ago
Publication history
No publication years on file
——
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

1 rowOpen in the library →
StudyTypeYearSummary depth
Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis.
Finding-3.52 kg/m² BMI reduction at 45 mg vs placebo.
Human—Full text read0.70